Information for "Early utilization of tocilizumab in people together with significant pneumonia secondary in order to serious intense respiratory malady coronavirus 2 disease as well as very poor prognostic conditions Affect mortality fee and rigorous care system entrance"
From EECH Central
Basic information
| Display title | Early utilization of tocilizumab in people together with significant pneumonia secondary in order to serious intense respiratory malady coronavirus 2 disease as well as very poor prognostic conditions Affect mortality fee and rigorous care system entrance |
| Default sort key | Early utilization of tocilizumab in people together with significant pneumonia secondary in order to serious intense respiratory malady coronavirus 2 disease as well as very poor prognostic conditions Affect mortality fee and rigorous care system entrance |
| Page length (in bytes) | 3,761 |
| Page ID | 1405173 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Trampair58 (Talk | contribs) |
| Date of page creation | 11:08, 25 April 2024 |
| Latest editor | Trampair58 (Talk | contribs) |
| Date of latest edit | 11:08, 25 April 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
